FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. USB 98 AX CNR NFK

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT François HIRSCH

(37 CFR 1.98(b)

FILING DATE May 25, 2001 GROUP

			U.S. PATE	ENT DOCUMENTS			
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
	AA						
	АВ						
	AC						
	F	OREIGN PATENT O	R PUBLISI	HED FOREIGN PATENT	APPLIC	ATION	
		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
W	AD .	WO 99/06040	02/99	International			N/A
	AE				,		
OTHER	DOC	UMENTS (Including	Author,	Title, Date, Relevant Pag	ges, Pla	ce of Pu	blication)
BF	AF۰	M.DIGICAYLIOGLU et al., NEUROPROTECTION FROM NITRIC OXIDE BY ERYTHROPOIETIN (EPO) IS MEDIATED BY NFKappaB, Society for Neuroscience, Part 2, Los Angeles, CA, November 7012, 1998					
	AG '	A.HAEFFNER et al, INHIBITORY EFFECT OF GROWTH HORMONE ON TNF-alpha SECRETION AND NUCLEAR FACTOR -kappaB TRANSLOCATION IN LIPOPOLYSACCHARIDE-STIMULATED HUMAN MONOCYTES, Journal of Immunology, Feb. 1, 1997, Vol. 3, No. 1, pp 1310-1314					
	ΑΗ̈́	C.Y.WANG et al., TNF- AND CANCER THERAPY-INDUCED APOPTOS- IS: POTENTIATION BY INHIBITION OF NF-kappaB", Science, Vol. 274, No. 5288, Nov. 1, 1996, pp 784-787					
BF	Αľ	A.HAEFFNER et al., GROWTH HORMONE PREVENTS HUMAN MONOCYTE CELL FROM FAS-MEDIATED APOPTOSIS BY UP-REGULATING Bcl-2 EXPRESSION, European Journal of Immunology, Vol. 29, No. 1, Jan. 1999, pp 334-44					
	AJ						
	AK						
	AL						
EXAMIN	ER	2 1/1/	. 1	DATE CONSIDERED)		

EXAMINER: Initial citation considered. Draw line through citation if not in confermance and net considered. Include copy of this form with n xt communication t applicant.